18471-73-3

Usage

Uses

Used in Chemical Synthesis Industry:
4-(2-Pyridyl)aniline is used as an intermediate for the synthesis of various organic compounds, contributing to the development of new chemical entities and materials.
Used in Pharmaceutical Industry:
4-(2-Pyridyl)aniline is used as a building block in the production of pharmaceuticals, playing a crucial role in the creation of new drugs and medicinal compounds.
Used in Dye and Pigment Industry:
4-(2-Pyridyl)aniline is used as a key component in the formulation of dyes and pigments, providing coloration and stability to various products.

InChI:InChI=1/C11H10N2/c12-10-6-4-9(5-7-10)11-3-1-2-8-13-11/h1-8H,12H2

Upstream product

• 109-09-1 2-chloropyridine 
• 106-40-1 4-bromo-aniline 
• 109-04-6 2-bromo-pyridine 
• 110-86-1 pyridine 
• 100-05-0 4-nitrobenzenediazonium chloride 
• 540-37-4 p-aminoiodobenzene 
• 14805-00-6 5-nitro-2,2’-bipyridine 
• 89415-43-0 (4-aminophenyl)boronic acid 
• 57785-86-1 pyridin-2-yl tosylate 
• 24067-17-2 4-nitrophenylboronic acid 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 100-01-6 4-nitro-aniline 
• 1008-89-5 2-phenylpyridine 
• 882521-96-2 pyridine-2-boronic acid N-phenyldiethanolamine ester 

Downstream Products

• 96265-38-2 N-(4-isopropoxy-phenyl)-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 102158-43-0 N-(4-dimethylamino-phenyl)-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 100395-32-2 N-methyl-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 102238-41-5 N-(4-ethoxy-phenyl)-N'-(4-[2]pyridyl-phenyl)-urea 
• 92-97-7 THC 
• 95131-06-9 N-(4-butoxy-phenyl)-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 95441-87-5 N-(4-isopentyloxy-phenyl)-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 95441-88-6 N-(4-pentyloxy-phenyl)-N'-(4-[2]pyridyl-phenyl)-thiourea 
• 51035-40-6 4-pyridin-2-yl-phenol 
• 5969-83-5 2-(4-chlorophenyl)pyridine 
• 63996-36-1 2-(4-bromophenyl]pyridine 
• 871012-88-3 2-(4-iodophenyl)pyridine 
• 898257-45-9 N,N-di(4-tert-butylphenyl)-4-(2-pyridyl)benzenamine 
• 99989-80-7 (4-[2]pyridyl-phenyl)-thiourea 

Relevant academic research and scientific papers

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Liquid crystal phosphorescent material based on cyclometalated complex and application thereof

The invention discloses a cyclometalated organic liquid crystal phosphorescent material based on 2-phenylpyridine as a main ligand and acetylacetone as an auxiliary ligand. A benzoic acid derivative liquid crystal unit is introduced into the main ligand 2

Phenoxazine-based supramolecular tetrahedron as biomimetic lectin for glucosamine recognition

The design and synthesis of a phenoxazine-based metal-organic tetrahedron (Zn4L4) as biomimetic lectin for selectively recognition of glucosamine (GlcN) was reported. Different from the free phenoxazine-based ligand (L), Zn4L4 displayed the highest fluorescent intensity enhancement efficiency toward GlcN over other related natural mono- and disaccharides. Fluorescence titration demonstrated a 1:1 stoichiometric host-guest complex was formed with an association constant about 4.03 × 104 L/mol. 1H NMR spectroscopic studies confirmed this selectivity resulted from the multiple hydrogen bonding interactions formed between GlcN and Zn4L4. The present results suggested that rational arrangement of recognition sites in the confined space of metal-organic cage is crucial for the selectivity toward target guests.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

Unified Protocol for Fe-Based Catalyzed Biaryl Cross-Couplings between Various Aryl Electrophiles and Aryl Grignard Reagents

The combination of commonly used FeCl3/SIPr with Ti(OEt)4/PhOM enabled a highly general iron-based catalyst system, which could efficiently catalyze the biaryl coupling reaction between various electrophiles (I, Br, Cl, OTs, OCONMe2, OSO2NMe2) and common or functionalized aryl Grignard reagents with high functional group tolerance. Selective couplings of aryl iodides and bromides over the corresponding oxygen-based electrophiles have been achieved, and thus a terphenyl acid intermediate for anidulafungin was conveniently synthesized via an orthogonal coupling strategy.

Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives

A new series of theophylline analogues containing 1,2,3-triazoles with different amide groups (22-41) has been designed and synthesized, and their biological activities have been evaluated as potential anticancer agents. The anticancer activities of the synthesized compounds were studied in four cancer cell lines viz. lung (A549), colon (HT-29), breast (MCF-7) and melanoma (A375). Furthermore, these compounds were screened for computational ADME and Lipinski's analysis followed by molecular docking and binding energy calculations against the various therapeutic targets involved in cell proliferation. The in vitro results demonstrate that compounds 22, 27, 36 and 40 have pivotal anticancer activity. Among these, compounds 22 and 27 have significant cytotoxic activity in all three cell lines; the in silico docking studies also reveal that compounds 22, 27 and 36 have good dock scores, binding affinities and binding energies towards human epidermal growth factor receptor 2. This is the first report to demonstrate theophylline hybrids containing 1,2,3-triazoles as potential anticancer agents.

Structure-activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs

Alpha7 nicotinic acetylcholine receptors (nAChRs) have implications in the regulation of cognitive processes such as memory and attention and have been identified as a promising therapeutic target for the treatment of the cognitive deficits associated with schizophrenia and Alzheimer's disease (AD). Structure affinity relationship studies of the previously described α7 agonist SEN12333 (8), have resulted in the identification of compound 45, a potent and selective agonist of the α7 nAChR with enhanced affinity and improved physicochemical properties over the parent compound (SEN12333, 8).

Synthesis of new bioorganometallic Ir- and Rh-complexes having β-lactam containing ligands

The synthesis (and full spectroscopic and crystallographic characterization) of new classes of bioorganometallic Ir- and Rh-complexes having β-lactam containing ligands has been achieved in three steps starting from simple precursors. The procedure for preparing these bioorganometallic compounds uses β-lactams having a phenylpyridyl moiety attached to the C4, N1 or C4 and N1 positions simultaneously, and a directed C-H metal-insertion, in the presence of (MCp*Cl2)2 (M = Ir, Rh). Enantiomerically pure 2-azetidinones can be transformed into diastereomeric (at the metal) mixtures of enantiopure metalla-2-azetidinones. Bimetallic 2-azetidinones are also accessible by this approach. The insertion of electron-poor alkynes into the M-C bond of the bioorganometallic complex occurs regioselectively and in excellent yields. Overall, the sequence imine-β-lactam-metalla-β-lactam is a versatile and efficient full methodology to prepare and functionalize unprecedented, novel Ir- and Rh-complexes having β-lactam containing ligands.

COMPOUND HAVING NPY Y5 RECEPTOR ANTAGONIST ACTIVITY

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.

COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY

This invention provides a compound of the formula (I): a pharmaceutically acceptable salt or solvate thereof, wherein R1 is substituted or unsubstituted alkyl or the like, R2 is hydrogen or substituted or unsubstituted alkyl, Ring A is monocyclic or bicyclic aromatic heterocycle, R3 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycle, R4 is halogen, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl or the like, m is an integer between 0 and 2, n is an integer between 0 and 5, R is halogen, oxo, cyano, nitro, substituted or unsubstituted alkyl or the like, and p is an integer between 0 and 2 as novel compounds having NPY Y5 antagonistic activity.